Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat Combinations in R/R PTCL
NCT07209163Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tazemetostat in peripheral T-cell lymphoma (PTCL), sponsored by Ruijin Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tazemetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07209163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209163.